0.53
+32.77%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Akebia Therapeutics
From its filings with the US Securities and Exchange Commission
Akebia Therapeutics is based in Waltham, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker AKBA. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $236.2m and a net loss of $5.3m. At that date it held total assets of $376.6m and shareholders' equity of $32.6m. By business, Product revenue, net brought in 96.2% of revenue, followed by License, collaboration and other revenue at 3.8%.
We are a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. We have built a business focused on developing and commercializing innovative therapeutics that we believe serve as a foundation for future growth, including by contributing net product revenue to support the development and advancement of our robust pipeline of mid-stage programs targeting rare kidney diseases and early-stage programs targeting kidney disease and non-kidney focused indications.
We have established the Company as a leader in the kidney community and believe our cross-organizational expertise in kidney disease positions us for success. Chronic kidney disease, or CKD, is a condition in which the kidneys are progressively damaged to the point that they cannot properly filter the blood circulating in the body. This damage causes waste products to build up in the patient’s blood, leading to other health problems, including anemia, cardiovascular disease and bone disease. CKD significantly impacts the United States, or U.S., healthcare system, potentially affecting approximately 35.5 million patients. In 2022, in the U.S. treating Medicare beneficiaries with CKD cost an estimated $95.7 billion, and treating people on dialysis cost an estimated $45.3 billion. Our two commercial products address certain complications of kidney disease.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 20 Mar 2014
- Employees
- 194
- Website
- akebia.com ↗
- Head office
- 180 THIRD AVENUE, WALTHAM, MA, 02451
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Adrian AdamsIndependent Chairman of the Board$165,333
- Mr. John ButlerPresident, Chief Executive Officer, Director, since 2013$4.3m
- Mr. Erik OstrowskiSenior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer$1.2m
- Dr. Steven BurkeSenior Vice President - Research and Development, Chief Medical Officer$1.8m
- Mr. Nicholas GrundSenior Vice President, Chief Commercial Officer$1.9m
- Mr. Ronald FriesonIndependent Director$142,833
- Dr. Steven GilmanIndependent Director$135,333
- Mr. Michael RogersIndependent Director$142,833
- Ms. Cynthia SmithIndependent Director$142,833
- Dr. Myles WolfIndependent Director$137,833
- Ms. Leanne ZumwaltIndependent Director$137,833
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 54
- Environment
- 59
- Social
- 48
- Governance
- 54
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Akebia Therapeutics Inc has several strengths that contribute to its competitive advantage in the market. Firstly, the company demonstrates strong expertise in the development of innovative therapeutics, particularly in the field of kidney diseases. This expertise allows Akebia to create effective and novel treatment options for patients, setting them apart from the competition. Additionally, Akebia Therapeutics possesses a robust portfolio of intellectual property rights and patents. This provides the company with legal protection and exclusivity for its innovative products, preventing competitors from easily replicating their successes. Furthermore, Akebia Therapeutics has established strategic partnerships and collaborations with renowned pharmaceutical companies. These partnerships not only provide access to additional resources and expertise but also enhance the company's credibility and reputation within the industry. Lastly, Akebia Therapeutics has a dedicated and talented team of researchers, scientists, and professionals who are committed to advancing the company's mission of improving patient outcomes. This highly skilled workforce enables Akebia to stay at the forefront of medical advancements and deliver high-quality therapeutics to the market.
Weaknesses
- Despite its strengths, Akebia Therapeutics Inc also faces certain weaknesses that could hinder its growth and competitive position. Firstly, the company relies heavily on the success of its pipeline products. Any setbacks or failures in the clinical development of these products may significantly impact the company's financial performance and overall reputation. Additionally, Akebia Therapeutics operates in a highly regulated industry, requiring compliance with strict regulatory standards and significant investment in research and development. This can pose financial and resource constraints for the company, limiting its ability to quickly bring new products to market. Furthermore, Akebia Therapeutics may face challenges related to market acceptance and competition. The pharmaceutical industry is highly competitive, with numerous established players competing for market share. Successfully commercializing new products and gaining market acceptance can be challenging and time-consuming. Lastly, Akebia Therapeutics may face risks related to dependence on key partners and collaborators. Any changes in these partnerships, such as termination or loss of intellectual property rights, could negatively impact the company's operations and future growth prospects.
Opportunities
- Akebia Therapeutics Inc has several opportunities to leverage and capitalize on in the market. Firstly, the increasing global prevalence of kidney diseases presents a substantial opportunity for the company to address unmet medical needs and capture a larger market share. By developing effective and innovative therapeutics, Akebia can position itself as a key player in the treatment of kidney diseases. Moreover, advancements in technology and understanding of disease mechanisms offer opportunities for Akebia Therapeutics to explore new treatment approaches and expand its therapeutic portfolio. The company can invest in research and development to discover novel drug candidates and strengthen its competitive position. Additionally, Akebia Therapeutics can explore strategic partnerships and collaborations with academic institutions and research organizations. These collaborations can provide access to novel technologies, scientific expertise, and potential funding sources, facilitating the development of new therapies and strengthening the company's research capabilities. Lastly, the growing trend towards personalized medicine and precision therapies allows Akebia Therapeutics to tailor its treatments to individual patients. By leveraging personalized medicine approaches, the company can enhance treatment efficacy and patient outcomes while differentiating itself from competitors.
Threats
- Akebia Therapeutics Inc faces several threats that could have a negative impact on its business and market position. Firstly, the pharmaceutical industry is subject to stringent regulations and compliance requirements, which can pose challenges for approval and commercialization of new products. Delays or failures in obtaining regulatory approvals can significantly hinder the company's ability to generate revenue and expand its market presence. Moreover, the competitive landscape within the pharmaceutical industry is intensifying. Akebia Therapeutics faces competition from both established pharmaceutical companies and emerging biotechnology firms. These competitors may develop similar or more effective therapeutics, eroding Akebia's market share and posing challenges for commercial success. Additionally, changes in healthcare policies or reimbursement systems can impact the affordability and accessibility of Akebia's therapeutics. Reductions in healthcare budgets or changes in reimbursement rates may limit patient access to Akebia's products, affecting the company's financial performance. Lastly, evolving market dynamics and economic uncertainties can pose risks for Akebia Therapeutics. Market volatility, fluctuating exchange rates, and economic downturns can impact the company's revenue streams, profitability, and ability to secure funding for research and development.
- In conclusion, Akebia Therapeutics Inc has a solid foundation of strengths, but it also faces challenges and uncertainties. By capitalizing on its strengths, proactively addressing weaknesses, exploring opportunities, and mitigating threats, Akebia can position itself for long-term success and growth in the competitive pharmaceutical industry.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.